Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Melanoma highlights from ESMO 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 30.09.19
Views: 1731
Rating:

Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany

Dr Teresa Amaral speaks to ecancer at ESMO 2019 in Barcelona about melanoma studies that stood out at the conference.

Dr Amaral begins by talking about research in the neoadjuvant setting, including the 2-year follow-up results of a large phase II trial looking at TVEC in neoadjuvant treatment versus surgery alone in patients with resectable stage IIIB-IVM1a melanoma and two Dutch trials that were presented investigating the combination of ipilimumab and nivolumab. She also comments on the biomarker study analysis being presented at the conference with regards to immunotherapy.

In the advanced melanoma setting, she comments on the 3-year efficacy and biomarker results from the CheckMate 238 trial, discusses what the IMMUNED study results meant for the recommended duration of combined immunotherapy and talks about what can be understood from the 5-year update results from the CheckMate 067 trial.

Dr Amaral also explains why the data presented on the ABC trial - which is an update on the combination of nivolumab and ipilimumab versus nivolumab alone in patients with asymptomatic melanoma brain metastases - indicates that it is important to provide this combination in the first-line setting.

To conclude, Dr Amaral summarises many of the shared aspects of the above studies, and suggests what clinicians can take away from the highlights of this meeting.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation